Eminase (Wulfing Pharma GmbH)

Eminase (Wulfing Pharma GmbH) - General Information

Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.

Pharmacology of Eminase (Wulfing Pharma GmbH)

Eminase (Wulfing Pharma GmbH) cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

Additional information about Eminase (Wulfing Pharma GmbH)

Eminase (Wulfing Pharma GmbH) Indication: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Mechanism Of Action: Eminase (Wulfing Pharma GmbH) cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Anistreplase
Synonyms: Tissue-type plasminogen activator precursor; t- PA; t-plasminogen activator; tPA
Drug Category: Thrombolytic Agents
Drug Type: Biotech; Approved

Other Brand Names containing Anistreplase: Eminase (Wulfing Pharma GmbH);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Eminase (Wulfing Pharma GmbH): Powder, for solution Intravenous
Chemical IUPAC Name: Human tissue plasminogen activator
Chemical Formula: C2569H3928N746O781S40
Anistreplase on Wikipedia: https://en.wikipedia.org/wiki/Anistreplase
Organisms Affected: Humans and other mammals